The Conversation (0)
June 03, 2025
Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
29 August 2025
Appendix 4E and Preliminary Final Report
Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
29 July 2025
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
27 July 2025
RAD receives IND approval from US FDA for Betabart (RV-01)
Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
10 June 2025
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
01 June 2025
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data
Radiopharm Theranostics (RAD:AU) has announced RAD Reports Positive Preclinical Lu177-B7H3-mAb DataDownload the PDF here. Keep Reading...
17 June
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
More People Than Ever Taking GLP-1 Drugs for Weight Loss Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms,... Keep Reading...
17 June
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
(TheNewswire) More people than ever taking GLP-1 drugs for weight loss Growing list of diseases now indicated as treatable with GLP-1 drugs Kelowna, British Columbia TheNewswire - June 17, 2026 Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug... Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
(TheNewswire) Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ Kelowna, British Columbia - June 9, 2026 TheNewswire - Lexaria Bioscience Corp. (NASDAQ: LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery... Keep Reading...
09 June
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECHâ„¢ KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing... Keep Reading...
03 June
Immunotherapy Innovations: Increasing Survival in Metastatic Breast Cancer
Metastatic breast cancer (MBC) remains incurable, with approximately only one-third of diagnosed women meeting the five year survival rate.Subtypes like triple-negative breast cancer (TNBC) or heavily pretreated hormone receptor-positive disease often come with more treatment challenges, leading... Keep Reading...
03 June
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00